Three former bosses of UK nurse Lucy Letby, convicted of killing babies, arrested on suspicion of manslaughter
The three senior staff members, who have not been named by police, worked at the Countess of Chester Hospital in 2015 and 2016 at the same time as Letby. All three suspects have been released on bail after being questioned by police on Monday.
'It is important to note that this does not impact on the convictions of Lucy Letby for multiple offences of murder and attempted murder,' Cheshire Constabulary Detective Superintendent Paul Hughes said in a statement.
The aspect of the investigation related to the latest arrests focuses on the 'grossly negligent action or inaction of individuals,' police said. Meanwhile, another ongoing part of the investigation into the separate offence of corporate manslaughter 'focuses on senior leadership and their decision making to determine whether any criminality has taken place concerning the response to the increased levels of fatalities.'
Letby, 34, was found guilty of murdering seven children and attempting to murder seven more between June 2015 and June 2016 while working in the neonatal unit of the hospital in Chester, England. The former nurse is serving 15 whole-life sentences.
The court heard during the case in 2023 that Letby attacked babies in her care by administering air into their blood and stomachs, overfeeding them with milk, physically assaulting them, and poisoning them with insulin.
However, her convictions have been criticized after an international panel of experts raised questions regarding the medical evidence.
The panel said there was no medical evidence indicating murder and that the babies' collapses resulted from 'either natural causes or bad medical care.'
It also highlighted issues of unsafe delays in diagnosis and treatments at Countess of Chester Hospital and said that in some cases staff were working 'probably beyond their expected ability or designated level of care,' according to the British Medical Journal (BMJ).
Last week, former UK Health Secretary Jeremy Hunt called for an 'urgent reexamination' after experts raised 'serious and credible' questions.
Independent experts 'are saying there is no medical evidence in the 17 deaths that were examined in the trial of what they call maleficence, of malicious intent,' Hunt said in an interview with Good Morning Britain, calling for a speedy review by the UK's Criminal Cases Review Commission. 'If they are saying that, then I really think we need to do this.'
'I am not arguing that Letby is innocent. That is not my place… The pain endured by the families affected must also be at the forefront of our minds,' Hunt wrote in a separate op-ed published in the Daily Mail newspaper last month, arguing that the families deserve the truth. 'And if medical error was the cause, we can then make sure no more babies die from the same mistakes.'
Letby has maintained her innocence and her lawyer Mark McDonald submitted an application earlier this year for her case to be reviewed by the commission. Letby's previous attempts to overturn her convictions have been refused by the court.
McDonald told the UK's PA Media on Tuesday that a proper and full public inquiry into failings by the hospital's neonatal and pediatric medical care unit is needed.
'The concerns many have raised will not go away, and we will continue to publicly discuss them,' McDonald said, according to PA. 'The reality is that 26 internationally renowned experts have looked at this case and the lead expert has concluded that no crime was committed, no babies were murdered.'
A public government inquiry is set to be published in early 2026. That inquiry previously heard evidence from the senior hospital leadership about the concerns raised regarding the rise in infant deaths at the neonatal unit, and the actions taken as a result.
Cheshire Police said they were continuing to investigate 'the deaths and non-fatal collapses of babies at the neo-natal units of both the Countess of Chester Hospital and the Liverpool Women's Hospital,' at which Letby undertook training placements. The elements of the investigation related to corporate manslaughter and gross negligence manslaughter are also ongoing, police said.
A spokeswoman for the Countess of Chester Hospital said it 'would not be appropriate' for the hospital to comment due to 'the ongoing police investigations' and public inquiry, PA reported.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
2 hours ago
- CNBC
London stock market could weather its biggest blow yet if AstraZeneca exits
Pressure is piling on London's stock exchange, with reports that British pharma giant AstraZeneca may move its listing to the U.S. delivering yet another blow this week. CEO Pascal Soriot is considering moving the company's stock listing from London to the U.S., British newspaper The Times reported on Tuesday afternoon, citing anonymous sources. Soriot's frustrations with the U.K.'s regulatory environment — particularly rules around new medicine approvals and drug pricing systems — are said to be driving the move. AstraZeneca declined to comment on the Times report. The company's exit from the U.K. market would spark a major index re-weighting, given AstraZeneca is the most valuable business listed on London's FTSE 100. AstraZeneca's market cap was £161.2 billion ($221.1 billion) as of Tuesday's closing price, according to LSEG data. AstraZeneca's potential transatlantic move would add to concerns around London's weakening status as a global financial hub. A number of companies have delisted from the London market or reconsidered plans to float shares in the city over the past year. Toni Meadows, head of investment at London's BRI Wealth Management, labeled AstraZeneca's rumored listing considerations as "disappointing" for the U.K. equity market — but he conceded that "it is not surprising" given that it would form the latest development in a wider established trend. Earlier this year, reports emerged that Chinese fast fashion giant Shein was looking to list in Hong Kong instead of London, when it goes public. Last week, news agency Reuters reported that the company was planning to file confidentially for a Hong Kong IPO. Metals investor Cobalt Holdings, meanwhile, confirmed to CNBC last month that it had scrapped plans for a London IPO, while British fintech giant Wise announced in June that it was moving its primary listing from London to New York. Kristo Kaarmann, Wise's CEO and co-founder, said in a statement at the time that the move would help raise awareness of the company in the U.S., while giving the firm better access to "the world's deepest and most liquid capital market." Companies listed in London have historically had much lower valuations than their Wall Street counterparts. Research from British investment manager Rathbones last year showed that the forward price-to-earnings ratio for U.K. stocks was 32% lower than those listed in the U.S. on a like-for-like basis. On the flipside, the Financial Times reported last week that Norwegian software giant Visma had chosen London for its upcoming debut on the public market. "Large and important companies like AstraZeneca are seeking a valuation uplift from exposure to a wider investor base and they will get that from moving to a US listing," BRI's Meadows told CNBC via email on Wednesday. "The trend to move listing, or the stream of takeovers for UK listed stocks, highlights value in the UK equity market, but it does nothing to encourage a new supply of companies listing here to support the future standing of the index in a Global context," Meadows added. Claire Trachet, founder of M&A advisory Trachet, said AstraZeneca shifting its listing to New York would represent "a memorable loss" for the London Stock Exchange. "Given the complexity of the company, this isn't simply because of liquidity or valuation advantages often cited by departing firms, rather a trifecta of underperforming capital markets, regulatory constraints, and misaligned incentives that make it harder to scale and reward innovation at home," she told CNBC by email. Trachet added that London-listed companies with a combined value in excess of $100 billion had already made the move to New York in recent years — and AstraZeneca's departure alone would more than double that figure. "The potential move makes it painfully clear to global markets that the UK is losing its edge on the needs of world-class, scale-driven companies," she said. "This isn't an isolated story — and that's the biggest issue. It's part of a broader shift, where founders and boards are increasingly looking to the US for deeper capital, stronger support, and a more ambitious investor base." Tom Bacon, a London-based partner at global law firm BCLP — which has a division dedicated to M&A and corporate finance — labeled reports of AstraZeneca's Soriot's desire to shift away from London "very worrying." "I think this should sound the alarm for the UK government that they need to do more both to support the city and our stock market together with our critical industries like life sciences and pharmaceuticals," he said. Dan Coatsworth, investment analyst at AJ Bell, on Wednesday said that AstraZeneca's reported plans appeared to be driven by business needs rather than chasing a higher valuation — but he added that moving the company's listing across the Atlantic "won't be an easy move to pull off." "Unlike many other UK market 'defectors' with a dominant US shareholder base like CRH and Flutter, AstraZeneca has a more geographically diverse pool of investors," he explained in an email. However, Coatsworth noted that AstraZeneca generates around 42% of its sales from the U.S., and already has plans to increase its operational footprint in the country. Earlier this year, CEO Soriot told CNBC AstraZeneca was "very committed to the United States," where the company has two large research and development centers. AJ Bell's Coatsworth told CNBC that AstraZeneca's CEO could also see a full U.S. stock listing as a "stepping stone to receiving better treatment Stateside." European pharmaceutical companies are facing uncertainty around their future in the American market, where U.S. President Donald Trump has threatened to impose sector-specific tariffs on drug imports. While the industry was exempted from Trump's so-called reciprocal tariffs plans when they were unveiled in April, the White House leader has since placed the sector under investigation by the U.S. Commerce Department, warned tariffs on pharma are "coming soon," and signed an executive order directing medicine manufacturers to lower the price of some drugs in line with costs paid overseas.
Yahoo
14 hours ago
- Yahoo
Three former bosses of UK nurse Lucy Letby, convicted of killing babies, arrested on suspicion of manslaughter
Three people who were part of the senior leadership team at the hospital where nurse and convicted child serial killer Lucy Letby worked have been arrested on suspicion of gross negligence manslaughter, British police said Tuesday. The three senior staff members, who have not been named by police, worked at the Countess of Chester Hospital in 2015 and 2016 at the same time as Letby. All three suspects have been released on bail after being questioned by police on Monday. 'It is important to note that this does not impact on the convictions of Lucy Letby for multiple offences of murder and attempted murder,' Cheshire Constabulary Detective Superintendent Paul Hughes said in a statement. The aspect of the investigation related to the latest arrests focuses on the 'grossly negligent action or inaction of individuals,' police said. Meanwhile, another ongoing part of the investigation into the separate offence of corporate manslaughter 'focuses on senior leadership and their decision making to determine whether any criminality has taken place concerning the response to the increased levels of fatalities.' Letby, 34, was found guilty of murdering seven children and attempting to murder seven more between June 2015 and June 2016 while working in the neonatal unit of the hospital in Chester, England. The former nurse is serving 15 whole-life sentences. The court heard during the case in 2023 that Letby attacked babies in her care by administering air into their blood and stomachs, overfeeding them with milk, physically assaulting them, and poisoning them with insulin. However, her convictions have been criticized after an international panel of experts raised questions regarding the medical evidence. The panel said there was no medical evidence indicating murder and that the babies' collapses resulted from 'either natural causes or bad medical care.' It also highlighted issues of unsafe delays in diagnosis and treatments at Countess of Chester Hospital and said that in some cases staff were working 'probably beyond their expected ability or designated level of care,' according to the British Medical Journal (BMJ). Last week, former UK Health Secretary Jeremy Hunt called for an 'urgent reexamination' after experts raised 'serious and credible' questions. Independent experts 'are saying there is no medical evidence in the 17 deaths that were examined in the trial of what they call maleficence, of malicious intent,' Hunt said in an interview with Good Morning Britain, calling for a speedy review by the UK's Criminal Cases Review Commission. 'If they are saying that, then I really think we need to do this.' 'I am not arguing that Letby is innocent. That is not my place… The pain endured by the families affected must also be at the forefront of our minds,' Hunt wrote in a separate op-ed published in the Daily Mail newspaper last month, arguing that the families deserve the truth. 'And if medical error was the cause, we can then make sure no more babies die from the same mistakes.' Letby has maintained her innocence and her lawyer Mark McDonald submitted an application earlier this year for her case to be reviewed by the commission. Letby's previous attempts to overturn her convictions have been refused by the court. McDonald told the UK's PA Media on Tuesday that a proper and full public inquiry into failings by the hospital's neonatal and pediatric medical care unit is needed. 'The concerns many have raised will not go away, and we will continue to publicly discuss them,' McDonald said, according to PA. 'The reality is that 26 internationally renowned experts have looked at this case and the lead expert has concluded that no crime was committed, no babies were murdered.' A public government inquiry is set to be published in early 2026. That inquiry previously heard evidence from the senior hospital leadership about the concerns raised regarding the rise in infant deaths at the neonatal unit, and the actions taken as a result. Cheshire Police said they were continuing to investigate 'the deaths and non-fatal collapses of babies at the neo-natal units of both the Countess of Chester Hospital and the Liverpool Women's Hospital,' at which Letby undertook training placements. The elements of the investigation related to corporate manslaughter and gross negligence manslaughter are also ongoing, police said. A spokeswoman for the Countess of Chester Hospital said it 'would not be appropriate' for the hospital to comment due to 'the ongoing police investigations' and public inquiry, PA reported.
Yahoo
14 hours ago
- Yahoo
3 new arrests in case of U.K. nurse convicted of murdering 7 infants
London — Three former senior leaders at the British hospital where nurse Lucy Letby was convicted of murdering seven babies have been arrested on suspicion of gross negligence manslaughter, police said Tuesday. All three were part of the senior leadership team at the Countess of Chester Hospital in the northwest of England between 2015 and 2016, when Letby was found to have killed the babies and attempted to kill seven others. Letby, 35, is serving 15 consecutive life sentences with no chance of parole, but there have been questions raised about the evidence used in her trial, and her lawyer has filed for a formal review of the case. In October 2023, following Letby's conviction, the Cheshire Constabulary police force launched an investigation into potential corporate manslaughter at the hospital, focusing on the decision-making of senior bosses, "to determine whether any criminality has taken place concerning the response to the increased levels of fatalities," according to a Tuesday statement by Detective Superintendent Paul Hughes. That investigation was widened to include the charge of gross negligence manslaughter, leading to the arrest of the three former leaders. All three have been released on bail pending further investigation, the police said. "Both the corporate manslaughter and gross negligence manslaughter elements of the investigation are continuing and there are no set timescales for these," Hughes said. "It is important to note that this does not impact on the convictions of Lucy Letby for multiple offenses of murder and attempted murder," he added. The Cheshire police are also investigating deaths and non-fatal collapses of babies at the neonatal units of the Countess of Chester Hospital and the Liverpool Women's Hospital between 2012 and 2016, where Letby did her training. Lucy Letby's controversial murder conviction Since her conviction, there have been significant concerns voiced over the evidence used to secure Letby's conviction, with The New Yorker, The Guardian, Private Eye and other outlets reporting on possible alleged flaws in the trial proceedings. In February, a group of experts held a news conference to dispute the medical evidence used to convict Letby. Dr. Shoo Lee, a retired Canadian neonatologist, said the group of 14 doctors had concluded that the newborns died either of natural causes or from insufficient medical care. "In summary then, ladies and gentlemen, we did not find murders," Lee said at the time Letby has maintained her innocence. Her defense attorney Mark McDonald said in April that the experts' findings had "completely demolished" the case against Letby, whom he argues was wrongly convicted. McDonald said he had submitted an application to the Criminal Cases Review Commission (CCRC), which has the power to send cases back to the Court of Appeal. The CCRC has given no date for when a decision might be reached. In a statement sent to CBS News on Tuesday, McDonald said that despite the news of the three new arrests, "the concerns many have raised will not go away, and we will continue to publicly discuss them." "What is needed is a proper and full public inquiry into the failings of the neonatal and paediatric medical care unit at the Countess of Chester hospital," McDonald said, repeating his assertion that Letby was wrongfully convicted. Jury has more questions in Sean "Diddy" Combs trial Details on the "Alligator Alcatraz" immigration detention center Last-minute rural health care change helped Senate pass Trump budget bill, lawmakers react
